Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-α and melphalan for bulky in-transit melanoma metastases

Carlo Riccardo Rossi, Mirto Foletto, Simone Mocellin, Pierluigi Pilati, Mario Lise

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Melphalan (L-PAM) hyperthermic isolated limb perfusion (HILP) is currently considered the standard treatment for patients with in-transit metastases from cutaneous melanoma. We here report on the results of L-PAM and low-dose tumor necrosis factor (TNF)α HILP in patients with bulky disease. Methods: Twenty patients underwent TNFα (1 mg) and L-PAM (10 mg/L) HILP. Perfusion was performed for 90 minutes, and systemic leakage was strictly monitored. Locoregional toxicity was evaluated according to Wieberdink's criteria, whereas tumor response was evaluated with physical examination and ultrasound scan with or without fine-needle aspiration of any suspected recurrence. Results: In all cases, systemic leakage was

Original languageEnglish
Pages (from-to)173-177
Number of pages5
JournalAnnals of Surgical Oncology
Volume11
Issue number2
DOIs
Publication statusPublished - 2004

Keywords

  • Isolated limb perfusion
  • Melanoma
  • Melphalan
  • TNFα

ASJC Scopus subject areas

  • Oncology
  • Surgery

Fingerprint Dive into the research topics of 'Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-α and melphalan for bulky in-transit melanoma metastases'. Together they form a unique fingerprint.

Cite this